Zobrazeno 1 - 10
of 280
pro vyhledávání: '"Terry W. Moody"'
Publikováno v:
Biology, Vol 12, Iss 7, p 957 (2023)
The ErbB RTKs (EGFR, HER2, HER3, and HER4) have been well-studied in cancer. EGFR, HER2, and HER3 stimulate cancer proliferation, principally by activating the phosphatidylinositol-3-kinase and extracellular signal-regulated kinase (ERK) pathways, re
Externí odkaz:
https://doaj.org/article/bb4059854e944339987df6802f5c8166
Autor:
Terry W. Moody, Lingaku Lee, Irene Ramos-Alvarez, Tatiana Iordanskaia, Samuel A. Mantey, Robert T. Jensen
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
G-protein-coupled receptors (GPCRs) are increasingly being considered as possible therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth effects, and GPCRs are frequently over-/ectopically expressed on tumors and thus
Externí odkaz:
https://doaj.org/article/9dc83171ba4748c3a0890f861c85137d
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Neuropeptide G protein-coupled receptors (GPCRs) are overexpressed on numerous cancer cells. In a number of tumors, such as small cell lung cancer (SCLC), bombesin (BB) like peptides and neurotensin (NTS) function as autocrine growth factors whereby
Externí odkaz:
https://doaj.org/article/ca3a76d176184c8f8fec7790f01850f1
Autor:
Terry W. Moody, Nicole Tashakkori, Samuel A. Mantey, Paola Moreno, Irene Ramos-Alvarez, Marcello Leopoldo, Robert T. Jensen
Publikováno v:
Frontiers in Endocrinology, Vol 8 (2017)
While peptide antagonists for the gastrin-releasing peptide receptor (BB2R), neuromedin B receptor (BB1R), and bombesin (BB) receptor subtype-3 (BRS-3) exist, there is a need to develop non-peptide small molecule inhibitors for all three BBR. The BB
Externí odkaz:
https://doaj.org/article/89b118da576445d1a02a4cc4cbcd7c38
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Mammalian bombesin (Bn) receptors comprise 3 subtypes: BB1, BB2, BB3 (nomenclature recommended by the NC-IUPHAR Subcommittee on bombesin receptors, [117, 4]). BB1 and BB2 are activated by the endogenous ligands neuromedin B (NMB), gastrin-releasing p
Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3
Publikováno v:
Peptides. 156
Neurotensin (NTS) receptor 1 regulates the growth non-small cell lung cancer (NSCLC) cells. NTS binds with high affinity to NTSR1, leading to increased tyrosine phosphorylation of the EGFR and HER2. Using Calu3, NCI-H358, or NCI-H441 cells, the effec
Publikováno v:
Cancer Research. 83:3071-3071
Pituitary adenylate cyclase activating polypeptide [PACAP] is a 27 amino acid peptide which stimulates the growth of numerous cancers including non-small cell lung cancer (NSCLC). PACAP binds with high affinity to the type B G protein-coupled recepto
Autor:
Terry W. Moody, Robert T. Jensen
Publikováno v:
Curr Opin Endocrinol Diabetes Obes
Purpose of review To discuss recent advances of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in pharmacology, cell biology, and intracellular signaling in cancer. Recent findings Recent stud
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2021
Mammalian bombesin (Bn) receptors comprise 3 subtypes: BB1, BB2, BB3 (nomenclature recommended by the NC-IUPHAR Subcommittee on bombesin receptors, [115]). BB1 and BB2 are activated by the endogenous ligands neuromedin B (NMB), gastrin-releasing pept
Autor:
Terry W. Moody
Publikováno v:
Ann N Y Acad Sci
Neuropeptides function as neuromodulators in the brain, whereby they are released in a paracrine manner and activate G protein-coupled receptors (GPCRs) in adjacent cells. Because neuropeptides are made in, and secreted from, cancer cells, then bind